In that study, non-responding depressed patients taking an SSRI or SNRI who were treated with adjunctive SAM-e achieved two- to three-fold greater response and remission rates than nonresponding depressed patients taking an SSRI or SNRI who were treated with adjunctive placebo
While this finding needs to be replicated, it suggests the greatest promise for a product like SAM-e may lie with adjunctive use rather than as monotherapy treatment
The adjunctive treatment approach using SJW is potentially problematic given its propensity for causing pharmacokinetic drug interactions